Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insmed’s SomatoKine causes controversy
Results from a pivotal phase II clinical trial initiated by Insmed have shown that SomatoKine, a once daily insulin-like growth factor I replacement therapy, can help children with
Results from a pivotal phase II clinical trial initiated by Insmed have shown that SomatoKine, a once daily insulin-like growth factor I replacement therapy, can help children with
The single-masked phase I/II clinical study of the investigational drug Lucentis (ranibizumab) demonstrated an ability to maintain vision in patients with wet age-related macular degeneration (AMD) when used
The priority review status means the company could have a decision in only six months time, rather than the 10 months wait usually applied to such decisions. This
The company believes that this is the first time a direct antiviral drug has reached this stage of clinical testing for this patient population. More than 170 treatment
The British pharmaceutical company sought to restrict supplies of its patented medicines to third-party distributors, requesting quotas to be imposed to prevent traders purchasing their medicines in lower-cost
The new program, known as ePedigree, comes as drug industry analysts estimate that nearly 10% of drugs worldwide are counterfeit. The World Health Organization has also reported that
The patent covers methods for the treatment of breast cancer by the administration of long-acting analogues of the peptide hormone oxytocin. The patent contains a total of 11
The cream will be administered using Transport’s drug-delivery system. The herpes product delivers acyclovir, an approved treatment for cold sores, directly to impacted skin at concentrations up to
The companies hope the project will lead to the creation of a national standard platform that will help secure the flow of prescription medicines from factory to pharmacy
Spectrum is now in a position to conduct a phase I/II trial with D 63153 in hormone-dependent prostate cancer and, thereby, expand the clinical development of D 63153